at MarketWatch.com (May 7, 2014)
Corcept Therapeutics (CORT) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients. The firm expects to launch of Korlym within the next two to three months, with consensus sales forecasts for the drug running as high as $409M by 2016. Shares +68.1% premarket.
From other sites